Stock GSK GSK PLC
Add to a list
To use this feature you must be a member
Log inSign up

GSK plc Stock

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe
Other stock markets
 03:30:20 2024-09-06 am EDT 		5-day change 1st Jan Change
1,639.75 GBX +0.05% Intraday chart for GSK plc -1.33% +12.74%
08:49am GSK's Nucala Drug Cuts COPD Exacerbations in Late-stage Study MT
08:43am GSK's Asthma Treatment Shows Positive Results for Chronic Obstructive Pulmonary Disease DJ
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site

Valuation: GSK plc

Capitalization 66.85B 88.16B P/E ratio 2024 *
12.9x
P/E ratio 2025 * 10.5x
Enterprise value 78.8B 104B EV / Sales 2024 *
2.49x
EV / Sales 2025 * 2.26x
Free-Float
94.54%
Yield 2024 *
3.68%
Yield 2025 * 3.9%
More valuation ratios * Estimated data

Chart: GSK plc

Dynamic Chart

Latest news: GSK plc

GSK's Nucala Drug Cuts COPD Exacerbations in Late-stage Study MT
GSK's Asthma Treatment Shows Positive Results for Chronic Obstructive Pulmonary Disease DJ
EDX Medical Group Names New Chief Commercial Officer MT
Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and Secretary CI
GSK: to present its advances at the Vienna Congress CF
UK's FTSE 100 Joins European Rally on US Economy Surge MT
GSK: RSV vaccine indication extended in the EU CF
Stocks tick higher as investors prep for US GDP AN
GSK hails EU approval of RSV jab Arexy for 50-59 year olds AN
Stocks called up as market awaits US GDP figures AN
GSK's RSV Vaccine Receives Additional EU Approval MT
GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease CI
European Equities Close Mostly Higher in Wednesday Trading; Incoming HSBC CEO Mulls Staff Cuts MT
More news

Last Transcript: GSK plc

Logo GSK plc
GSK plc, Q2 2024 Earnings Call, Jul 31, 2024
More transcripts

Analysts' recommendations: GSK plc

GSK : Goldman Sachs reaffirms its Neutral rating ZD
GSK : Berenberg maintains buy recommendation, target 1820 pence CF
GSK : Gets a Buy rating from Berenberg ZD
GSK : Goldman Sachs gives a Neutral rating ZD
GSK : JP Morgan reiterates its Sell rating ZD
More recommendations

Press Releases: GSK plc

GSK aims to redefine the future of respiratory medicine at the European Respiratory Society International Congress | GSK AQ
GSK : aims to redefine the future of respiratory medicine at the European Respiratory Society International Congress PU
European Commission approves expanded age indication for GSK's Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk | GSK AQ
GSK plc - Zantac litigation, Delaware Supreme Court to review Superior Court's Daubert decision AQ
Bepirovirsen granted SENKU designation in Japan for chronic hepatitis B | GSK AQ
More press releases

News in other languages: GSK plc

GSK-Asthmamittel Nucala auch gegen COPD wirksam
GSK : va présenter ses avancées au Congrès de Vienne
GSK : indication étendue dans l'UE pour le vaccin VRS
Les Bourses rivées sur les résultats du géant des puces Nvidia
Actualización de las fuertes variaciones del día: buenas noticias de GSK, Givaudan, FlatexDeGiro y Lhyfe
More news

Quotes and Performance

1 day-0.20%
1 week-1.39%
Current month-1.39%
1 month+7.39%
3 months-0.37%
6 months-2.34%
Current year+12.67%
More quotes

Course Extremes

1 week
1 632.50
Extreme 1632.5
1 671.00
1 month
1 518.50
Extreme 1518.5
1 671.00
Current year
1 453.20
Extreme 1453.2
1 823.50
1 year
1 365.22
Extreme 1365.217
1 823.50
3 years
1 280.92
Extreme 1280.92
3 408.16
5 years
1 280.92
Extreme 1280.92
3 408.16
10 years
1 280.92
Extreme 1280.92
3 408.16
More quotes

Managers and Directors: GSK plc

Director TitleAgeSince
Emma Walmsley CEO
 Chief Executive Officer 55 10-04-30
Julie Brown DFI
 Director of Finance/CFO 62 23-04-30
James Ford CMP
 Compliance Officer - 95-07-31
Manager TitleAgeSince
Emma Walmsley CEO
 Chief Executive Officer 55 10-04-30
Jesse Goodman BRD
 Director/Board Member 72 15-12-31
Hal Barron BRD
 Director/Board Member 62 17-12-31
More insiders

ETFs: GSK plc

Name Weight AuM 1st Jan change Investor Rating
ISHARES CURRENCY HEDGED MSCI UNITED KINGDOM ETF - USD ETF iShares Currency Hedged MSCI United Kingdom ETF - USD
3.17% 11 M€ +0.83% -
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
3.15% 18 M€ +7.76% -
FIRST TRUST INTERNATIONAL CAPITAL STRENGTH ETF - CAD ETF First Trust International Capital Strength ETF - CAD
2.51% 7 M€ +8.56% -
More ETFs: GSK plc

Other Pharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
GSK PLC Stock GSK plc
-0.20%-1.39%+18.70%-12.16%87.95B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
-3.55%-2.92%+63.52%+251.69%822B
NOVO NORDISK A/S Stock Novo Nordisk A/S
-1.20%-6.41%+32.29%+175.67%583B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.42%+0.46%+2.68%-5.74%397B
ABBVIE INC. Stock AbbVie Inc.
-2.11%-1.19%+32.01%+72.78%341B
MERCK & CO., INC. Stock Merck & Co., Inc.
+2.41%+0.96%+10.31%+53.49%301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+0.22%-5.11%+18.76%+45.70%256B
ROCHE HOLDING AG Stock Roche Holding AG
-0.71%-4.35%+8.84%-25.27%262B
NOVARTIS AG Stock Novartis AG
-1.02%-4.30%+12.06%+16.86%236B
AMGEN INC. Stock Amgen Inc.
-1.90%-2.01%+27.70%+43.29%174B
Average -0.30%-2.12%+22.69%+61.63% 345.99B
Weighted average by Cap. -0.26%-2.33%+29.63%+105.02%
See all sector performances

Financials

2024 *2025 *
Net sales 31.64B 41.72B 33.39B 44.03B
Net income 5.15B 6.79B 6.44B 8.49B
Net Debt 11.95B 15.75B 8.55B 11.28B
More financial data * Estimated data

Company Profile

Logo GSK plc
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Employees
70,212
Sector
Pharmaceuticals
Calendar
2024-09-06 - European Respiratory Society Congress - Oral No #RCT3718
Related indices
STOXX Europe 600 Index (EUR) , FTSE 100
More about the company

Quotes

Date Price Change Volume
24-09-06 1,635.50 p -0.21% 151,162
24-09-05 1,639.00 p -1.50% 6,668,398
24-09-04 1,664.00 p +0.54% 3,190,669
24-09-03 1,655.00 p +0.27% 7,947,444
24-09-02 1,650.50 p -0.39% 5,002,812

Delayed Quote London S.E., September 06, 2024 at 03:05 am EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
16.39GBP
Average target price
19.68GBP
Spread / Average Target
+20.07%
Consensus
Profit revisions
Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GSK Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW